Interestingly, we identified an upregulation of the stress-activated mitogen kinase p38 as well as one member of the p38 signaling pathway—i.e., the MAPK activated protein kinase 3 (MAPKAPK3)—in a mouse tumor that developed under AKT/mTOR treatment in comparison with a mouse tumor that developed in an untreated control mouse. The gene discussed is AKT1; the disease is neoplasm.